DT-PACE

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Trappist the monk (talk | contribs) at 12:51, 22 April 2019 (→‎top: Fix multiple names in cs1|2 template |author= parameters (and aliases);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

DT-PACE refers to a chemotherapy regimen for multiple myeloma consisting of Dexamethasone, Thalidomide, Cisplatin or Platinol, Adriamycin or doxorubicin, Cyclophosphamide, and Etoposide. [1]

References

  1. ^ Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G (2003). "DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma". J Clin Oncol. 21: 2732–9. doi:10.1200/JCO.2003.01.055. PMID 12860952.

External links


Stub icon

This oncology article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=DT-PACE&oldid=893595133"